Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, the latest drugmaker to boost its U.S. manufacturing amid President Donald Trump's tariff threats.

A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the opening of a new, $1 billion, 225,000-square-foot facility dedicated to vaccine manufacturing at its Durham ...

Merck MRK stock has declined 7.8% in the past month — in roughly the span after it announced fourth-quarter 2024 results and ...

Merck opened a 225,000-square-foot facility dedicated solely to expanding vaccine manufacturing. The Rahway-based research-intensive biopharmaceutical announced the launch of the $1 billion ...

but contained only reprinted or summarized articles--most of which presented data favorable to Merck products--that appeared to act solely as marketing tools with no disclosure of company sponsorship.

Merck & Co., Inc. is a health care company ... animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.

The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the Wilmington-area location. If Merck accepts the grant, the company would be required to create 375 ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK may work for income investors.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck ... technological advances, new products and patents attained by competitors; challenges inherent ...